CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company develops, manufactures and markets a range of plasma-derived and recombinant therapies worldwide. At the Bern site, CSL Behring AG employs more than 1,800 people who apply their know-how and dedication to manufacturing the high-quality biotherapeutics made from human plasma, which meet the highest safety standards.